AI-supported system for monitoring and preventing adverse drug reactions

An AI-powered system addresses under-reporting and incomplete data in pharmacovigilance by integrating diverse data sources for real-time ADR detection and personalized interventions, enhancing patient safety and reducing healthcare costs.

DE202024105013U1Active Publication Date: 2024-11-14PORANKI KRUPA RANI +12
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
DE202024105013
Authority / Receiving Office
DE · DE
Patent Type
Utility models
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-14
Estimated Expiration
2034-09-30

AI Technical Summary

Technical Problem

Current pharmacovigilance systems face challenges such as under-reporting, incomplete data, lack of real-time monitoring, and insufficient personalization, leading to inadequate detection and prevention of adverse drug reactions (ADRs).

Method used

An AI-powered system that integrates multiple data sources, uses advanced machine learning techniques for real-time analysis, and provides personalized interventions to detect and prevent ADRs, ensuring regulatory compliance.

Benefits of technology

Enhances patient safety by enabling early detection and personalized prevention of ADRs, reducing healthcare costs and improving pharmacovigilance efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

An AI-powered system for monitoring and preventing adverse drug reactions (ADRs), which includes the following: ◯ a data acquisition module (101) configured to collect and aggregate data from multiple sources, including electronic health records (EHRs), clinical trial data, pharmacy records, and patient-reported outcomes; ◯ a data processing module (102) that applies natural language processing (NLP) techniques to unstructured data and standardizes structured data for integration into a unified dataset; ◯ an AI-powered analysis engine (103) that uses machine learning (ML) algorithms to analyze the unified dataset, identify patterns and correlations that indicate potential adverse drug reactions (ADRs), and assess the risk associated with the identified ADRs in real time; ◯ a real-time monitoring dashboard (104) configured to display alerts, detected adverse drug reactions, risk levels and recommended interventions for healthcare providers; ◯ a preventive measures module (105) that generates personalized recommendations based on the patient's health profile and the analysis performed by the AI-supported machine, with the recommendations aiming to mitigate the identified adverse drug reaction (ADR) risks; and ◯ a regulatory compliance and reporting module (106) that automatically generates standardized reports for detected adverse drug reactions in accordance with pharmacovigilance regulations.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION:

[0001] The present invention relates to the field of healthcare and pharmacovigilance. More specifically, it concerns a system and method for monitoring, detecting, and preventing adverse drug reactions (ADRs) using artificial intelligence (AI) and machine learning (ML) techniques. BACKGROUND OF THE INVENTION:

[0002] Adverse drug reactions (ADRs) pose a significant and ongoing challenge to the medical and pharmaceutical industries. An ADR is defined as an undesirable or harmful reaction that occurs following the administration of a drug or combination of drugs under normal conditions of use and imposes a significant burden on patients and healthcare systems. ADRs can range from mild symptoms to severe, life-threatening conditions and are a leading cause of morbidity and mortality worldwide. Current challenges:

[0003] Despite advances in medical science, the detection and prevention of adverse drug reactions remain inadequate. Traditional pharmacovigilance relies on spontaneous reporting (SRS) systems, where healthcare professionals or patients voluntarily report suspected adverse drug reactions. While these systems play a crucial role in identifying potential drug safety issues, they suffer from underreporting, delayed reporting, and incomplete data, which limit their effectiveness.

[0004] Studies suggest that only a small percentage of ADRs are ever reported, and those that are reported often lack the detailed information required for comprehensive analysis. Another major challenge is the complexity and variability of ADRs. Factors such as genetic predisposition, drug-drug interactions, patient comorbidities, and lifestyle choices can influence the likelihood and severity of ADRs. Conventional methods often fail to account for these variables, leading to inaccurate assessments and delayed interventions. The role of Big Data and AI:

[0005] With the proliferation of electronic health records, wearable devices, and other digital health tools, an unprecedented amount of health data is available that could be used to improve the detection and prevention of adverse events. However, the sheer volume and diversity of this data pose a significant challenge for traditional data analysis methods.

[0006] Artificial intelligence (AI), or more specifically, machine learning (ML), offers a promising solution to these challenges. AI algorithms are exceptionally capable of processing large amounts of data and detecting complex patterns that may be undetectable to human analysts. By using AI, it is possible to detect adverse drug reactions earlier and more accurately, predict which patients are at higher risk, and develop personalized prevention strategies. Previous efforts and limitations:

[0007] Several attempts have been made to use AI and ML in pharmacovigilance. Some systems have successfully demonstrated the ability to identify previously unknown ADRs by analyzing large datasets, such as electronic health records or social media posts. However, these systems often face limitations, including: 1. Data quality and integration: Integrating and harmonizing data from different sources (e.g., clinical trials, electronic health records, patient reports) is a complex task. Inconsistent data formats, missing information, and privacy concerns can compromise the effectiveness of AI models. 2. Lack of real-time capabilities: Many existing systems analyze data retrospectively, delaying the identification of adverse events. A real-time monitoring system is essential for timely intervention and preventing harm to patients. 3. Challenges of personalization: Most AI systems in pharmacovigilance do not adequately account for individual differences between patients. Personalized medicine requires models that can adapt to each patient's unique characteristics, such as genetics, lifestyle, and concomitant medication use. 4. Regulatory compliance: Another major challenge is ensuring that AI-driven ADR monitoring systems meet strict regulatory requirements. The lack of standardized reporting and the potential for biased or opaque AI models raise concerns among regulators.

[0008] The need for an advanced ADR monitoring and prevention system: Given the limitations of existing systems and the increasing complexity of pharmacovigilance, there is an urgent need for an advanced, AI-powered solution that can comprehensively address these challenges. Such a system should be able to: • Integration of various data sources in real time to obtain a holistic overview of patient health status and drug interactions • Use of sophisticated AI models that can detect adverse drug reactions early and predict potential risks with high accuracy • Offer personalized preventive measures based on individual patient profiles • Ensure full compliance with legal requirements while maintaining transparency and accountability in AI decision-making

[0009] The present invention aims to meet this need by providing an AI-powered adverse drug reaction monitoring and prevention system that combines cutting-edge AI techniques with robust data integration and real-time monitoring capabilities. This system is designed to significantly improve patient safety, reduce the incidence of ADRs, and increase the overall efficiency of pharmacovigilance practices. SUMMARY OF THE INVENTION:

[0010] The present invention provides an AI-based adverse drug reaction (ADR) monitoring and prevention system that improves patient safety through continuous monitoring, detection, and prevention of adverse drug reactions (ADRs). The system integrates data from various sources, including electronic health records (EHRs), patient reports, and clinical trials, to provide a comprehensive overview of patient health status and drug interactions.

[0011] The system features an AI-powered analytics engine that leverages advanced machine learning (ML) techniques such as deep learning and natural language processing (NLP) to analyze large data sets and identify potential adverse drug reactions in real time. A real-time monitoring dashboard provides healthcare professionals with timely alerts and insights, allowing them to take immediate action to prevent adverse reactions.

[0012] To further mitigate ADR risks, the system includes a preventive intervention module that recommends personalized strategies based on individual patient profiles, such as alternative medications or dosage adjustments. A continuous learning loop allows the system to improve its accuracy and predictive capabilities over time by incorporating user feedback on the effectiveness of interventions.

[0013] Furthermore, the system is equipped with a regulatory compliance and reporting module that automatically generates standardized reports for ADRs, ensuring compliance with international pharmacovigilance regulations. The invention aims to revolutionize pharmacovigilance practices by providing a scalable, accurate, and proactive solution for monitoring and preventing ADRs, ultimately improving patient outcomes and reducing healthcare costs. SHORT DESCRIPTION OF THE DRAWING:

[0014] The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated into and constitute a part of this specification. The drawings illustrate exemplary embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure. Fig.shows a block diagram of an AI-supported system (100) for monitoring and preventing adverse drug reactions according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE INVENTION:

[0015] The AI-based Adverse Drug Reaction Monitoring and Prevention System (100) is a comprehensive solution for improving the safety and efficacy of drug therapies through the use of advanced artificial intelligence (AI) techniques. This system (100) aims to overcome the limitations of current pharmacovigilance practices by providing a proactive and personalized approach to real-time monitoring, detection, and prevention of adverse drug reactions (ADRs).

[0016] At the heart of the system (100) is an AI-powered analytics engine (103) that processes and analyzes massive amounts of data from various sources, including electronic health records (EHRs), clinical trial data, pharmacy records, patient-reported outcomes, and real-world insights. The data ingestion process by the data ingestion module (101) is designed to handle both structured and unstructured data, ensuring the system (100) can effectively handle various types of information. Structured data, such as lab results and medication records, are seamlessly integrated with unstructured data, such as clinical notes and patient feedback, using natural language processing (NLP) techniques.Through this integration, the system (100) can extract meaningful insights from different data formats, providing a comprehensive overview of the patient's health status and potential drug interactions.

[0017] Once the data has been acquired by the data acquisition module (101) and preprocessed by the data processing module (102), the AI-powered analytics engine (103) applies a combination of machine learning (ML) models, including deep learning algorithms, to detect patterns and anomalies that may indicate potential ADRs. These models are trained on large-scale datasets, allowing them to detect complex relationships between patient variables, drug characteristics, and adverse effects. By analyzing these patterns, the system (100) can identify high-risk scenarios that may lead to adverse drug reactions even before symptoms manifest.

[0018] The system (100) is designed to operate in real time, continuously monitoring patient data to provide timely alerts to healthcare professionals and actionable insights. A user-friendly real-time monitoring dashboard (104) is an integral part of the system (100) and provides healthcare providers with an intuitive interface for visualizing detected adverse drug reactions, risk levels, and suggested interventions. This dashboard is highly customizable, allowing users to set specific thresholds and alerts based on their clinical preferences and patient needs. When the system (100) detects a potential adverse drug reaction, it generates an alert that is immediately displayed on the dashboard, allowing healthcare professionals to take prompt action to mitigate risk.

[0019] In addition to real-time monitoring and detection, the system (100) includes a preventive measures module (105) that goes beyond mere risk identification. This module uses the insights gained by the AI ​​engine to recommend personalized interventions tailored to the individual patient. For example, if a patient is at high risk for a particular adverse effect due to their genetic profile or concomitant medication, the system (100) can suggest alternative drug therapies, dosage adjustments, or additional monitoring protocols. These recommendations aim to optimize therapeutic outcomes while minimizing the risk of adverse effects, making the system (100) a valuable tool for personalized medicine. A key feature of the invention is the feedback loop and the ability for continuous learning.

[0020] The system (100) is designed to evolve and improve over time by incorporating feedback from healthcare professionals about the accuracy of its predictions and the effectiveness of recommended interventions. This feedback is used to retrain and refine the AI ​​models so that the system (100) adapts to emerging trends and new data, thereby improving its predictive accuracy and reliability. Through this continuous learning process, the system (100) will become increasingly better at detecting and preventing adverse drug reactions over time.

[0021] To ensure regulatory compliance, the system (100) includes a regulatory compliance and reporting module (106) that automates the generation of ADR reports in accordance with local and international pharmacovigilance regulations. This module streamlines the reporting process, reduces the administrative burden for healthcare providers, and ensures that all detected ADRs are documented and accurately reported. The system's ability to generate standardized reports not only facilitates regulatory compliance but also contributes to global drug safety monitoring. Overall, the AI-supported system for monitoring and preventing adverse drug reactions (100) represents a significant advance in the field of pharmacovigilance.

[0022] By combining cutting-edge AI technologies with robust data integration and real-time monitoring capabilities, the system (100) offers a proactive solution for the management of ADRs. It increases patient safety by enabling early detection and intervention, reduces healthcare costs associated with ADR-related hospitalizations, and supports personalized medicine through tailored therapy recommendations. This invention has the potential to revolutionize the way adverse drug reactions are managed by providing a scalable, efficient, and intelligent approach to protecting patient health.

[0023] The AI-powered adverse drug reaction monitoring and prevention system (100) works through a seamless integration of data collection, real-time analytics, and personalized interventions, all orchestrated by advanced artificial intelligence (AI) algorithms. The system (100) begins by continuously collecting a variety of data from multiple sources, including electronic health records (EHRs), clinical trial data, pharmacy records, and patient-reported outcomes. This data is critical for creating a comprehensive profile of each patient, including their medical history, current treatments, genetic predispositions, and lifestyle factors.

[0024] After data is ingested, it undergoes a thorough preprocessing phase by the data processing module (102), where it is cleaned, standardized, and anonymized to ensure consistency and data protection. Structured data such as lab results and medication records are reconciled with unstructured data such as clinical notes and patient feedback. Natural Language Processing (NLP) techniques are used to extract relevant information from text data and transform it into a structured format that can be effectively analyzed.

[0025] After the data is prepared, the system's (100) AI-powered analytics engine (103) comes into play. This engine uses a combination of machine learning (ML) models, including deep learning algorithms, to sift through the massive data sets. These models have been trained on extensive historical data and are capable of identifying complex patterns and relationships between patient variables, drug characteristics, and adverse drug reactions. The system (100) continuously monitors incoming data in real time, looking for signs that could indicate a potential adverse drug reaction (ADR). For example, it can detect an abnormal lab result, a change in a patient's symptoms, or a drug interaction that increases the risk of an adverse drug reaction.

[0026] When the system (100) detects a potential adverse drug reaction, it immediately generates an alert. This alert is communicated to healthcare providers via a real-time monitoring dashboard (104), which serves as the user interface of the system (100). The dashboard is designed to be intuitive and user-friendly, allowing healthcare professionals to quickly assess the situation and make informed decisions. It provides detailed information about the detected ADR, the patient's current health status, and the associated risk. Furthermore, the dashboard offers personalized recommendations for interventions generated by the system (100) based on the patient's individual profile.

[0027] These preventive interventions are a key aspect of the system's functionality (100). By analyzing patient data in conjunction with the identified risk, the system (100) suggests specific measures that can be taken to prevent the occurrence of the ADR. For example, it may recommend adjusting the dosage of a specific medication, switching to an alternative therapy, or implementing additional monitoring protocols. These recommendations are designed to be actionable and clinically relevant, helping healthcare providers tailor their treatment plans to each patient's individual needs.

[0028] A unique feature of the system (100) is its ability for continuous learning. After performing a procedure, healthcare providers can feed the results back into the system (100). This feedback is used to retrain and refine the AI ​​models, allowing the system (100) to improve its predictive accuracy over time. This allows the system (100) to become increasingly better able to detect and prevent unwanted side effects and adapt to new medications, new healthcare trends, and evolving clinical practices.

[0029] In addition to monitoring and intervention, the system (100) also addresses the legal aspects of pharmacovigilance. It includes a compliance and reporting module that automates the generation of ADR reports. These reports are standardized to meet the requirements of local and international regulatory authorities, ensuring that all detected ADRs are documented and reported in a timely manner. This automation not only reduces the administrative burden for healthcare providers but also increases the overall efficiency of the pharmacovigilance process.

[0030] Overall, the AI-powered adverse drug reaction monitoring and prevention system (100) acts as an intelligent, proactive tool that significantly improves healthcare providers' ability to ensure patient safety. By combining real-time data analytics with personalized interventions and continuous learning, the system (100) offers a transformative approach to managing the risks associated with drug therapies, ultimately improving patient outcomes and advancing the field of pharmacovigilance. LIST OF REFERENCE SYMBOLS 100 AI-supported system for monitoring and preventing adverse drug reactions 101 Data acquisition module 102 Data processing module 103 AI-powered analytics engine 104 Real-time monitoring dashboard 105 Module for preventive measures 106 Regulatory Compliance and Reporting Module

Claims

[1] An AI-based system for monitoring and preventing adverse drug reactions (ADRs) that includes: ◯ a data ingestion module (101) configured to collect and aggregate data from multiple sources, including electronic health records (EHR), clinical trial data, pharmacy records, and patient-reported outcomes; ◯ a data processing module (102) that applies natural language processing (NLP) techniques to unstructured data and standardises structured data for integration into a unified data set; ◯ an AI-based analytics engine (103) that uses machine learning (ML) algorithms to analyse the unified dataset, identify patterns and correlations indicative of potential ADRs and assess the risk associated with the identified ADRs in real time; ◯ a real-time monitoring dashboard (104) configured to display alerts, detected ADRs, risk levels and recommended interventions for healthcare providers; ◯ a preventive measures module (105) that generates personalized recommendations based on the patient’s health profile and the analysis performed by the AI-assisted machine, with recommendations aimed at mitigating the identified ADR risks; and ◯ a regulatory compliance and reporting module (106) that automatically generates standardised reports for detected ADRs in accordance with pharmacovigilance regulations. [2] The system (100) of claim 1, wherein the machine learning algorithms used by the AI-powered analytics engine (103) comprise deep learning models based on historical patient data, drug interactions, and known adverse drug reactions. [3] The system (100) of claim 1, wherein the real-time monitoring dashboard (104) is customizable so that healthcare providers can set specific thresholds and configure alarms according to their clinical preferences and patient-specific needs. [4] The system (100) of claim 1, wherein the preventive action module (105) is further configured to provide alternative medication options, dosage adjustments, or additional monitoring protocols based on the identified ADR risk and the individual health characteristics of the patient. [5] The system (100) of claim 1, wherein the regulatory compliance and reporting module (106) is further configured to automatically submit the generated reports to the appropriate regulatory authorities, thereby facilitating compliance with local and international pharmacovigilance standards.

Citation Information

Cited By

  • Marine carbon sink data acquisition and real-time analysis system

    CN118962032A

  • Breast cancer patient whole-course intelligent individual case management system and method

    CN120032909A